Back to search
IDH1-mutant Glioma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which IDH1-mutant Glioma trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which IDH1-mutant Glioma trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade…
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in parti…
A vision-language model using preoperative MRI and clinical variables has been developed to simultaneously predict three key molecular markers in midline glioma…
The purpose of this study is to determine the safety and efficacy of a PEPIDH1M vaccine in combination with vorasidenib, a dual inhibitor of mutant IDH1 and IDH…
This phase II trial studies how well olaparib works in treating patients with glioma, cholangiocarcinoma, or solid tumors with IDH1 or IDH2 mutations that has s…
This study will test the hypothesis that vorasidenib in combination with lomustine will be safe and tolerable. The overall goal of this study is to identify the…